Related Experiment Video
Updated: Jul 22, 2026
10:04
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
Predicting malignancy grade with PET in non-Hodgkin's lymphoma
M Rodriguez1, S Rehn, H Ahlström
1Department of Diagnostic Radiology, University of Uppsala, Akademiska Sjukhuset, Sweden.
Summary
18-Fluorodeoxyglucose (18FDG) positron emission tomography (PET) can predict malignancy grade in non-Hodgkin's lymphoma (NHL). However, 11C-methionine PET cannot differentiate between high- and low-grade NHL.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiochemistry
Background:
- Non-Hodgkin's lymphoma (NHL) is a heterogeneous group of lymphoid malignancies.
- Accurate grading of NHL is crucial for treatment selection and prognosis.
- Positron emission tomography (PET) imaging is increasingly used in oncology for diagnosis and staging.
Purpose of the Study:
- To evaluate the efficacy of 11C-methionine and 18-Fluorodeoxyglucose (18FDG) PET in predicting the malignancy grade of non-Hodgkin's lymphoma (NHL).
Main Methods:
- Twenty-three patients with high-grade, low-grade, or transformed low-grade NHL were included.
- Standardized uptake values (SUV), transport rate, and mass influx were calculated for both tracers.
- Quantitative uptake values were analyzed in mean regions of interest (ROI) and tumor 'hot spots'.
Main Results:
- Both 11C-methionine and 18FDG PET successfully detected all NHL tumors.
- 18FDG PET demonstrated the ability to discriminate between high- and low-grade NHL.
- 11C-methionine PET did not show significant differences between NHL grades; however, three transformed low-grade NHLs showed intermediate behavior with 18FDG.
Conclusions:
- 18FDG PET, unlike 11C-methionine PET, shows potential in predicting malignancy grade in NHL.
- Further research with larger patient cohorts is warranted to confirm these findings.
